NCT01589510

A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 419 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

A study of Lumigan® 0.01% as administered in standard practice for patients with POAG or OHT. All treatment decisions, care and diagnostic procedures provided are at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.

Conditions

• Glaucoma, Open-Angle
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	bimatoprost 0.01% ophthalmic solution	Bimatoprost 0.01% ophthalmic solution (Lumigan® 0.01%) as prescribed by physician per standard practice for up to 14 weeks.

Timeline

• Start date: 2012-04-01
• Primary completion: 2013-02-01
• Completion: 2013-02-01
• First posted: 2012-05-02
• Last updated: 2014-06-13
• Results posted: 2014-06-13

Locations

1 site across 1 country: Austria